Interaction of Both SH2 Domains of SHP-2 with a PD-1 Homodimer Is Required for PD-1-Mediated Inhibition of T Cell Responses
Nikolaos Patsoukis(Beth Israel Deaconess Medical Center), Vassiliki A. Boussiotis(Beth Israel Deaconess Medical Center), Anders H. Berg(Cedars-Sinai Medical Center), Kathleen M. Mahoney(Beth Israel Deaconess Medical Center), Kankana Bardhan(Seres Therapeutics (United States)), Gordon J. Freeman(Dana-Farber Cancer Institute), Jessica D. Weaver(Beth Israel Deaconess Medical Center)
Cited by 6
Related Papers
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
|Nature Immunology|2001|3k
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
|New England Journal of Medicine|2016|1.4k
PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation
|Nature Communications|2015|1.2k